» Articles » PMID: 35258103

Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies

Overview
Publisher Wiley
Specialty Pharmacology
Date 2022 Mar 8
PMID 35258103
Authors
Affiliations
Soon will be listed here.
Abstract

Antidepressants are known to cause hyponatremia, but conflicting evidence exists regarding specific antidepressants. To identify antidepressants less likely to cause hyponatremia, we conducted a triangulation study integrating retrospective cohort, disproportionality, and pharmacodynamic studies. In the retrospective cohort study of patients (≥ 60 years) in Nihon University School of Medicine's Clinical Data Warehouse (2004-2020), a significant decrease in serum sodium levels was observed within 30 days after initiation of a selective serotonin reuptake inhibitor (SSRI; mean change -1.00 ± 0.23 mmol/L, P < 0.001) or serotonin-noradrenaline reuptake inhibitor (SNRI; -1.01 ± 0.31 mmol/L, P = 0.0013), whereas no decrease was found for a noradrenergic and specific serotonergic antidepressant (mirtazapine; +0.55 ± 0.47 mmol/L, P = 0.24). Within-class comparison revealed no decrease in serum sodium levels for fluvoxamine (+0.74 ± 0.75 mmol/L, P = 0.33) among SSRIs and milnacipran (+0.08 ± 0.87 mmol/L, P = 0.93) among SNRIs. In the disproportionality analysis of patients (≥ 60 years) in the Japanese Adverse Drug Event Report database (2004-2020), a significant increase in hyponatremia reports was observed for SSRIs (reporting odds ratio 4.41, 95% confidence interval 3.58-5.45) and SNRIs (5.66, 4.38-7.31), but not for mirtazapine (1.08, 0.74-1.58), fluvoxamine (1.48, 0.94-2.32), and milnacipran (0.85, 0.45-1.62). Finally, pharmacoepidemiological-pharmacodynamic analysis revealed a significant correlation between the decrease in serum sodium levels and binding affinity for serotonin transporter (SERT; r = -0.84, P = 0.02), suggesting that lower binding affinity of mirtazapine, fluvoxamine, and milnacipran against SERT is responsible for the above difference. Although further research is needed, our data suggest that mirtazapine, fluvoxamine, and milnacipran are less likely to cause hyponatremia.

Citing Articles

Long-term benefit of SGLT2 inhibitors to prevent heart failure hospitalization in patients with diabetes, with potential time-varying benefit.

Takahashi Y, Minagawa K, Nagashima T, Hayakawa T, Akimoto H, Asai S Clin Transl Sci. 2024; 17(12):e70088.

PMID: 39692694 PMC: 11653944. DOI: 10.1111/cts.70088.


Comparison of the Incidence and Magnitude of Hyponatremia Among Patients With Poststroke Depression Receiving Either Escitalopram or Sertraline.

Naseralallah L, Noureddine Z, Koryash S Pharmacol Res Perspect. 2024; 12(6):e70041.

PMID: 39623741 PMC: 11612018. DOI: 10.1002/prp2.70041.


Hyponatremia Associated with the Use of Common Antidepressants in the All of Us Research Program.

Mo H, Channa Y, Ferrara T, Waxse B, Schlueter D, Tran T Clin Pharmacol Ther. 2024; 117(2):534-543.

PMID: 39540435 PMC: 11739749. DOI: 10.1002/cpt.3484.


The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds.

Gheysens T, Van Den Eede F, De Picker L Eur Psychiatry. 2024; 67(1):e20.

PMID: 38403888 PMC: 10966618. DOI: 10.1192/j.eurpsy.2024.11.


Vitamin D supplementation is effective for olanzapine-induced dyslipidemia.

Zhou Z, Nagashima T, Toda C, Kobayashi M, Suzuki T, Nagayasu K Front Pharmacol. 2023; 14:1135516.

PMID: 36895943 PMC: 9989177. DOI: 10.3389/fphar.2023.1135516.

References
1.
Mazhar F, Pozzi M, Gentili M, Scatigna M, Clementi E, Radice S . Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. CNS Drugs. 2019; 33(6):581-592. DOI: 10.1007/s40263-019-00631-5. View

2.
Takeuchi S, Takahashi Y, Asai S . Comparison of pleiotropic effects of statins vs fibrates on laboratory parameters in patients with dyslipidemia: A retrospective cohort study. Medicine (Baltimore). 2020; 99(50):e23427. PMC: 7738156. DOI: 10.1097/MD.0000000000023427. View

3.
Decaux G, Musch W . Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol. 2008; 3(4):1175-84. DOI: 10.2215/CJN.04431007. View

4.
Tatonetti N, Ye P, Daneshjou R, Altman R . Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012; 4(125):125ra31. PMC: 3382018. DOI: 10.1126/scitranslmed.3003377. View

5.
Lawlor D, Tilling K, Davey Smith G . Triangulation in aetiological epidemiology. Int J Epidemiol. 2017; 45(6):1866-1886. PMC: 5841843. DOI: 10.1093/ije/dyw314. View